Netarsudil mesylate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in open-angle glaucoma and ocular hypertension. Its therapeutic use is listed as ophthalmic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Netarsudil dimesylate and Netarsudil mesilate. Its PubChem CID is 90410375.
Netarsudil mesylate
| CAS No | 1422144-42-0 |
|---|---|
| Molecular Formula | C30H35N3O9S2 |
| Molecular Weight | 645.7 g/mol |
| Synonyms | [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;methanesulfonic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Netarsudil mesylate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in open-angle glaucoma and ocular hypertension.
The listed CAS number is 1422144-42-0.
The listed molecular formula is C30H35N3O9S2.
The listed molecular weight is 645.7 g/mol.
[4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;methanesulfonic acid.
The source lists Netarsudil dimesylate and Netarsudil mesilate.